Truist Financial Corp Magenta Therapeutics, Inc. Transaction History

Truist Financial Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 22, 2022	SELL	$2.55 - $5.23 $325,941 - $668,498	-127,820 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.43 - $8.33 $8,860 - $16,660	2,000 Added 1.59%	127,820 $566,000
Q3 2021 Nov 05, 2021	BUY	$6.07 - $9.89 $44,311 - $72,197	7,300 Added 6.16%	125,820 $916,000
Q2 2021 Aug 16, 2021	BUY	$9.76 - $14.15 $75,152 - $108,955	7,700 Added 6.95%	118,520 $1.16 Million
Q1 2021 May 17, 2021	SELL	$7.66 - $13.38 $164,690 - $287,670	-21,500 Reduced 16.25%	110,820 $1.31 Million
Q4 2020 Nov 19, 2021	SELL	$6.1 - $7.94 $9,394 - $12,227	-1,540 Reduced 1.15%	132,320 $1.04 Million
Q4 2020 Feb 18, 2021	BUY	$6.1 - $7.94 $27,694 - $36,047	4,540 Added 3.51%	133,860 $1.05 Million
Q3 2020 Nov 13, 2020	BUY	$6.52 - $8.94 $283,522 - $388,755	43,485 Added 50.66%	129,320 $879,000
Q2 2020 Aug 14, 2020	BUY	$6.18 - $10.76 $145,823 - $253,892	23,596 Added 37.91%	85,835 $645,000
Q1 2020 May 15, 2020	BUY	$6.03 - $15.24 $284,248 - $718,398	47,139 Added 312.18%	62,239 $391,000
Q4 2019 Feb 14, 2020	BUY	$9.07 - $15.84 $136,957 - $239,184	15,100 New	15,100 $229,000

442K

Ticker MGTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,890,500
Description
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that ca...

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Truist Financial Corp with notifications on news.